These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 7507184

  • 1. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change.
    Thali M, Charles M, Furman C, Cavacini L, Posner M, Robinson J, Sodroski J.
    J Virol; 1994 Feb; 68(2):674-80. PubMed ID: 7507184
    [Abstract] [Full Text] [Related]

  • 2. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ, McKeating JA, Schutten M, Reitz MS, Robert-Guroff M.
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [Abstract] [Full Text] [Related]

  • 3. A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex.
    Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV.
    J Virol; 2000 May; 74(9):4183-91. PubMed ID: 10756031
    [Abstract] [Full Text] [Related]

  • 4. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV.
    J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
    [Abstract] [Full Text] [Related]

  • 5. Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites.
    Watkins BA, Buge S, Aldrich K, Davis AE, Robinson J, Reitz MS, Robert-Guroff M.
    J Virol; 1996 Dec; 70(12):8431-7. PubMed ID: 8970964
    [Abstract] [Full Text] [Related]

  • 6. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.
    Wibmer CK, Gorman J, Ozorowski G, Bhiman JN, Sheward DJ, Elliott DH, Rouelle J, Smira A, Joyce MG, Ndabambi N, Druz A, Asokan M, Burton DR, Connors M, Abdool Karim SS, Mascola JR, Robinson JE, Ward AB, Williamson C, Kwong PD, Morris L, Moore PL.
    PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415
    [Abstract] [Full Text] [Related]

  • 7. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):877-87. PubMed ID: 21158699
    [Abstract] [Full Text] [Related]

  • 8. Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.
    Si Z, Cayabyab M, Sodroski J.
    J Virol; 2001 May; 75(9):4208-18. PubMed ID: 11287570
    [Abstract] [Full Text] [Related]

  • 9. Interactions of polyclonal and monoclonal anti-glycoprotein 120 antibodies with oligomeric glycoprotein 120-glycoprotein 41 complexes of a primary HIV type 1 isolate: relationship to neutralization.
    Fouts TR, Trkola A, Fung MS, Moore JP.
    AIDS Res Hum Retroviruses; 1998 May 01; 14(7):591-7. PubMed ID: 9591713
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins.
    Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, Broliden K.
    Proc Natl Acad Sci U S A; 1992 Jan 15; 89(2):461-5. PubMed ID: 1370580
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein.
    Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, Sodroski J.
    J Virol; 1992 Sep 15; 66(9):5635-41. PubMed ID: 1380099
    [Abstract] [Full Text] [Related]

  • 17. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.
    McCaffrey RA, Saunders C, Hensel M, Stamatatos L.
    J Virol; 2004 Apr 15; 78(7):3279-95. PubMed ID: 15016849
    [Abstract] [Full Text] [Related]

  • 18. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies.
    Back NK, Smit L, Schutten M, Nara PL, Tersmette M, Goudsmit J.
    J Virol; 1993 Nov 15; 67(11):6897-902. PubMed ID: 8411395
    [Abstract] [Full Text] [Related]

  • 19. Immunization with a soluble CD4-gp120 complex preferentially induces neutralizing anti-human immunodeficiency virus type 1 antibodies directed to conformation-dependent epitopes of gp120.
    Kang CY, Hariharan K, Nara PL, Sodroski J, Moore JP.
    J Virol; 1994 Sep 15; 68(9):5854-62. PubMed ID: 7520095
    [Abstract] [Full Text] [Related]

  • 20. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP, Ho DD.
    J Virol; 1993 Feb 15; 67(2):863-75. PubMed ID: 7678308
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.